Retatrutide: the triple-receptor agonist that achieved 24% mean body weight reduction in Phase 2 trials.

What Is Retatrutide?

Retatrutide is an investigational once-weekly injectable compound designated LY3437943 by Eli Lilly. It is a synthetic peptide of approximately 39 amino acids built on a GIP receptor agonist scaffold and conjugated to a fatty diacid moiety that extends its plasma half-life to approximately 6 days ^[2].

The defining feature of retatrutide is triple receptor agonism: it activates the GLP-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR) simultaneously. No approved obesity or diabetes drug achieves all three. That single distinction is what drives the compound's outsized Phase 2 weight loss numbers and is the basis for every study in the TRIUMPH Phase 3 program ^[12].

GLP-1R agonism suppresses appetite and slows gastric emptying. GIPR co-agonism amplifies glucose-dependent insulin secretion. GCGR activation adds a third lever — raising hepatic glucose output, stimulating lipolysis in adipose tissue, and increasing thermogenesis in brown adipose tissue, which raises basal energy expenditure ^[4]. The combination addresses both the calories-in and the calories-out sides of the energy balance equation at once — a mechanism not achievable by single or dual receptor agonists alone.

In the pivotal Phase 2 obesity trial (n=338, 48 weeks), the 12 mg arm achieved a mean body weight reduction of 24.2% versus 2.1% in the placebo group ^[1]. Sixty-three percent of pooled participants across dose groups lost at least 15% of body weight at 36 weeks in a subsequent meta-analysis ^[6].

How Retatrutide Differs From Single and Dual GLP-1 Agonists

Single GLP-1 receptor agonists lower body weight primarily through appetite suppression. Dual GLP-1/GIP agonists add an insulin-amplifying component. Retatrutide adds a third layer: glucagon receptor co-activation, which contributes an energy-expenditure increase that the other two receptor targets cannot produce on their own ^[21].

Preclinical calorie-intake-matched experiments in obese mice isolated this effect. Animals given retatrutide lost significantly more weight than those given a GLP-1/GIP dual agonist at equivalent dose conditions — and calorimetry confirmed the additional weight loss traced to increased energy expenditure driven by GCGR-activated thermogenesis ^[16]. The glucagon receptor component, in other words, is not redundant with GLP-1 or GIP activity; it is additive.

Cryo-EM structural analysis at sub-3 Å resolution confirmed how a single continuous helix in the retatrutide molecule can penetrate and activate all three receptor transmembrane domains ^[4]. Retatrutide is 8.9 times more potent at GIPR than the endogenous hormone GIP itself. At GLP-1R and GCGR it operates at 0.4x and 0.3x endogenous potency — a deliberately tuned potency hierarchy that allows co-activation of all three receptors without hyperstimulating any single axis.

Those structural insights, published in Cell Discovery in 2024 ^[4], explain why the weight loss magnitude seen in Phase 2 was higher than what the class had previously produced — and why the TRIUMPH-5 head-to-head Phase 3 trial is directly comparing retatrutide against a GLP-1/GIP dual agonist to determine whether that structural advantage translates to superior outcomes at the population level ^[20].

Phase 2 Results: What the Obesity and Diabetes Trials Measured

The Phase 2 obesity trial, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity or overweight and at least one weight-related comorbidity ^[1]. Participants were randomized to 1 mg, 4 mg, or 12 mg retatrutide once weekly or to placebo over 48 weeks. The dose-response relationship was clear:

• 1 mg arm: 8.7% mean body weight reduction
• 4 mg arm: 17.1% mean reduction
• 8 mg arm: 22.8% mean reduction
• 12 mg arm: 24.2% mean reduction
• Placebo: 2.1% reduction

In the concurrent Phase 2 type 2 diabetes trial (n=281, published in the Lancet in 2023), 82% of participants in the 8 mg cohort reached the HbA1c target of 6.5% or below at 36 weeks, with a mean HbA1c reduction of up to 2.02% ^[3].

A meta-analysis pooling three randomized controlled trials (n=640) confirmed that those results were not outliers ^[7]. The pooled data showed significant reductions in HbA1c, fasting glucose, VLDL cholesterol, AST, and systolic and diastolic blood pressure, alongside the weight loss figures. Risk ratios for weight loss thresholds versus placebo: 2.92 for 5% or more, 9.32 for 10% or more, 18.40 for 15% or more, and 16.61 for 20% or more.

For retatrutide dosage details, including the Phase 2 titration protocol and pharmacokinetics, see the dedicated dosage page.

The TRIUMPH Phase 3 Program: What Is Being Studied

The TRIUMPH program uses a basket-trial design across four Phase 3 studies — the first basket-trial structure in cardiometabolic drug development ^[12]. More than 5,800 participants are enrolled across studies evaluating retatrutide for:

• Obesity (co-primary: body weight reduction)
• Obstructive sleep apnea (co-primary: Apnea-Hypopnea Index change)
• Knee osteoarthritis (co-primary: WOMAC pain subscale)
• Cardiovascular and kidney outcomes (TRIUMPH-Outcomes, NCT06383390)

TRIUMPH-1 Phase 3 results reported approximately 28% mean body weight reduction at 48 weeks at the highest dose — the largest weight loss magnitude reported for any pharmacological obesity intervention in a Phase 3 trial as of 2026. TRIUMPH-5 (NCT06662383), launched November 2024, will provide the first direct head-to-head comparison against a dual GLP-1/GIP agonist ^[20].

Retatrutide is not FDA approved for any indication as of mid-2026. Access remains through Lilly-sponsored TRIUMPH Phase 3 trial results and affiliated studies. Full FDA approval status tracking is on the research page.

Beyond Obesity: Liver, Kidneys, Sleep, and Joints

The Phase 2 MASLD trial (n=98, published in Nature Medicine in 2024) measured hepatic fat fraction by MRI-PDFF at 24 weeks ^[5]. Retatrutide produced dose-dependent liver fat reductions: 42.9% relative reduction at 1 mg, 57.0% at 4 mg, 81.4% at 8 mg, and 82.4% at 12 mg versus a +0.3% change with placebo. Eighty-six percent of participants in the 12 mg arm achieved normal liver fat (below 5%). Fibrosis biomarkers — K-18 and pro-C3 — also improved significantly.

A post-hoc analysis of two Phase 2 trials examined kidney outcomes ^[9]. Retatrutide 12 mg reduced the urinary albumin-to-creatinine ratio by 37% in type 2 diabetes participants and by 31.5% in obesity participants without diabetes. eGFR showed dose-dependent increases of 5.3 to 8.5 mL/min per 1.73 m² at 8–12 mg in the obesity cohort. These findings led to a dedicated Phase 2b kidney trial — TRANSCEND-CKD — enrolling adults with overweight or obesity and chronic kidney disease ^[13].

The retatrutide side effects literature, including gastrointestinal adverse events and cardiovascular monitoring data, is covered on the dedicated safety page.